Advanced search
Publication Cover
Annals of Medicine Volume 56, 2024 - Issue 1
Submit an article Journal homepage
1,245
Views
0
CrossRef citations to date
0
Altmetric
Infectious Diseases

Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study

Xiaobo Hana College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaView further author information
,
Chenglong Lic National Institute of Health Data Science, Peking University, Beijing, China;d Institute of Medical Technology, Health Science Center of Peking University, Beijing, ChinaView further author information
,
Xin Yuane Pulmonary and Critical Care Medicine Department, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Junchang Cuia College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaView further author information
,
Zhihai Hanf Pulmonary and Critical Care Medicine Department, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Jiguang Mengg Pulmonary and Critical Care Medicine Department, The Fourth Medical Center, Chinese PLA General Hospital, Beijing, China;h Naval Clinical College, Anhui Medical University, Hefei, ChinaView further author information
,
Weiguo Zhaoa College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Fei Xiei Pulmonary and Critical Care Medicine Department, The First Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Kaifei Wangi Pulmonary and Critical Care Medicine Department, The First Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Yuhong Liua College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Guoxin Muoa College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Na Xij Pharmacy Department, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Mengli Zhenga College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaView further author information
,
Rentao Wanga College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaView further author information
,
Kun Xiaoa College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaView further author information
,
Wei Chenf Pulmonary and Critical Care Medicine Department, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Junchen Xiongf Pulmonary and Critical Care Medicine Department, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China;g Pulmonary and Critical Care Medicine Department, The Fourth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Dahui Zhaoi Pulmonary and Critical Care Medicine Department, The First Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Xinxin Zhanga College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Xinjie Hana College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Haibo Chengk Shandong Future Network Research Institute, Jiangsu Future Network Group Co., Ltd., Jiangsu, ChinaView further author information
,
Zhongkuo Yua College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaView further author information
,
Yinghan Shia College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaView further author information
,
Wuxiang Xiel Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China;m Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, ChinaCorrespondence[email protected]
View further author information
&
Lixin Xiea College of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China;b Chinese PLA Medical School, Beijing, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2313062 | Received 06 Aug 2023, Accepted 25 Jan 2024, Published online: 14 Feb 2024

References

  • Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1–10. doi: 10.1056/NEJMoa2118542.
  • Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge. N Engl J Med. 2022;387(9):790–798. doi: 10.1056/NEJMoa2204919.
  • Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342–e349. doi: 10.1093/cid/ciac443.
  • Salerno DM, Jennings DL, Lange NW, et al. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Am J Transplant. 2022;22(8):2083–2088. doi: 10.1111/ajt.17027.
  • Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2023;76(4):563–572. doi: 10.1093/cid/ciac673.
  • Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77–84. doi: 10.7326/M22-2141.
  • Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023;3099(23):696–70. doi: 10.1016/S1473-3099(23)00011-7.
  • World Health Organization. Therapeutics and COVID-19: living guideline. World Health Organization; [cited 2023 April 22]. Available from: https://files.magicapp.org/guideline/29b7d717-7bfd-415e-b642-cc70bf70ec1e/published_guideline_6141-10_0.pdf. Lancet Infect Dis. 2023;23(6):696–705, doi: 10.1016/S1473-3099(23)00011-7.
  • Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalized patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet. 2022;400(10359):1213–1222. doi: 10.1016/S1473-3099(22)00507-2.
  • Liu J, Pan X, Zhang S, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicentre randomized controlled study. Lancet Reg Health West Pac. 2023;33:100694. doi: 10.1016/j.lanwpc.2023.100694.
  • Deng G, Li D, Sun Y, et al. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J Med Virol. 2023;95(4):e28756. doi: 10.1002/jmv.28756.
  • Chinese Thoracic Society, Chinese Association of Chest Physicians Critical Care Group. Expert consensus on the treatment of severe COVID-19 caused by Omicron variants. Zhonghua Jie He He Hu Xi Za Zhi. 2023;46(2):101–110. doi: 10.3760/cma.j.cn112147-20221230-00994.
  • Gao Y, Luo Z, Ren S, et al. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19. J Infect. 2023;86(6):e158–e160. doi: 10.1016/j.jinf.2023.03.023.
  • Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi: 10.1016/S0140-6736(07)61602-X.
  • Charlson ME, Carrozzino D, Guidi J, et al. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8–35. doi: 10.1159/000521288.
  • WHO. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis; [cited 2023 Jan 9]. Available from: https://www.who.int/docs/default-source/blue-print/covid-19-therapeutic -trial-synopsis.pdf.
  • General Office of the National Health Commission. Diagnosis and treatment protocol for COVID-19 in China (trial version 9); [cited 2022 Oct 20]. Available from: https://www.gov.cn/zhengce/zhengceku/2022-03/15/content_5679257.htm.
  • Garibaldi BT, Wang K, Robinson ML, et al. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw Open. 2021;4(3):e213071. doi: 10.1001/jamanetworkopen.2021.3071.
  • Imai K, Ratkovic M. Covariate balancing propensity score. J R Stat Soc Series B Stat Methodol. 2014;76(1):243–263. doi: 10.1111/rssb.12027.
  • Therneau TM, Grambsch PM, Pankratz VS. Penalized survival models and frailty. J Comput Graph Stat. 2003;12(1):156–175. doi: 10.1198/1061860031365.
  • Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219–219. doi: 10.1136/bmj.326.7382.219.
  • Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomized factorial trial. Lancet. 2018;392(10145):400–408. doi: 10.1016/S0140-6736(18)31388-6.
  • Agrawal U, Katikireddi SV, McCowan C, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med. 2021;9(12):1439–1449. doi: 10.1016/S2213-2600(21)00380-5.
  • Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400(10360):1305–1320. doi: 10.1016/S0140-6736(22)01656-7.
  • Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. doi: 10.1038/s41586-020-2521-4.
  • Sun F, Lin Y, Wang X, et al. Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(9):1279. doi: 10.1016/S1473-3099(22)00430-3.
  • Chinese Center for Disease Control and Prevention. National report on novel coronavirus infection. 2023; [cited 2020 Jul 25]. Available from: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202301/t20230125_263519.html.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.